ABBOTT PARK, Ill., July 23, 2020
/PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received
approval from the U.S. Food and Drug Administration (FDA) for the
use of the company's Patient Controller app on compatible personal
Apple‡ smartphone devices. At Abbott, this approval allows patients
living with neurological conditions, including chronic pain or
movement disorders, the ability to manage therapy directly from
their personal smartphone.2
With this app approval, the need to carry a separate patient
programmer device is eliminated, streamlining the patient's
experience and seamlessly integrating therapy management into their
life. This is an important step in the integration and connection
of digital health tools that ultimately help patients live fuller,
healthier lives.
"For physicians who are prescribing and implanting
neuromodulation technologies, the ability to integrate therapies
into one's everyday life is key," said Alexander Escobar,
M.D., Clinical Assistant Professor of Anesthesiology and Pain
Medicine at The University of Toledo,
OH. "The COVID-19 global health crisis has demanded access to
virtual treatment options, especially for those individuals with
chronic medical conditions that may have difficulty coming to see
their physician or would prefer not to leave their own
home. To ensure our patients are receiving the care they need
in the appropriate setting, close follow up is
critical. Physicians have the ability to remain engaged with
their patients through the Apple device, allowing them to interact
and treat debilitating chronic pain."
"The ability to support the changing needs of individuals living
with debilitating chronic conditions, like Parkinson's, without
them having to leave their homes is vitally important in today's
world," said Drew Falconer, M.D.,
Director of the Parkinson's and Movement Disorders Center, Inova
Health System in Virginia.
"Abbott's NeuroSphere Digital Care solution, including the new
Patient Controller app, allows patients to handle one single device
and using the FaceTime application, interact with their provider
teams in a convenient, easy-to-use interface -- an important
attribute for those with tremors or have challenges with
mobility."
The Patient Controller app will be integrated into Abbott's
broader NeuroSphere Digital Care connected care management
platform, which became available in May. It is compatible with
Abbott's suite of neuromodulation technologies, including Infinity™
DBS System for patients with Parkinson's disease or essential
tremor, Proclaim™ XR SCS System for patients living with chronic
pain, and Proclaim™ DRG Neurostimulation System for patients with
chronic pain in the lower limbs caused by complex regional pain
syndrome or causalgia. This integration across all Abbott
neuromodulation technologies allows physicians to more easily treat
the individual needs of each patient within their practice who have
an Abbott device and Apple smartphone.
"Patients are seeking digital options to better engage with
their healthcare providers and manage their chronic conditions
remotely – and this has never been more evident than in today's
pandemic where virtual care is necessary," said Keith Boettiger, vice president,
Neuromodulation, Abbott. "With the continuing rise in interest and
demand for these technologies, Abbott, as a pioneer in
patient-centric neuromodulation technology, is advancing the field
of digital health to deliver on the promise of digital care. The
approval of Abbott's Patient Controller app with personalized
access to therapy is a landmark event, as we are now able to
provide patients a way to access personalized therapy from a
compatible and secure iOS device so that people can live their
lives and seamlessly manage conditions like chronic pain and
movement disorders."
The Patient Controller app with personalized access to therapy
will be made available starting in the coming weeks. For important
safety information please visit the websites for Infinity DBS,
Proclaim XR and Proclaim DRG devices.
™ Indicates a trademark of the Abbott group of companies. ‡
Indicates a third-party trademark, which is property of its
respective owner.© 2020 Abbott. All Rights Reserved.
1.
Separate from a medical device.
2. Available on eligible Apple‡ mobile digital devices. For a list
of personal Apple mobile digital devices compatible with Abbott's
Patient Controller app, visit
http://www.NMmobiledevicesync.com/dbs OR
www.NMmobiledevicesync.com/cp
About Abbott
Abbott is a global healthcare leader
that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
107,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
View original
content:http://www.prnewswire.com/news-releases/abbott-receives-fda-approval-for-ios-compatible-app-allowing-people-living-with-chronic-pain-and-movement-disorders-to-personalize-therapy-via-their-mobile-device-301098105.html
SOURCE Abbott